Observational Study on Prescribing Patterns of Antihypertensive Agent and Evaluation of Comorbidities in Hypertensive Patients
DOI:
https://doi.org/10.26452/fjphs.v2i3.270Keywords:
Antihypertensive Agents, Patients, Prescribing Patterns, ComorbiditiesAbstract
Appraise the prescribing patterns of anti hypertensive agents in the treatment of hypertension and related co-morbid conditions. To assess the prescribing patterns of medications in hypertensive patients. To study the demographics of patients associated with hypertension. To compare the differences in the prescribing patterns of antihypertensive drugs, with co morbidity conditions. Review on medication outcomes in hypertensive patients. To evaluate the rationality outcomes in hypertensive patients. To obtain the mean arterial blood pressure of an individual patient. The age group 40-69 has more affected females followed by males at age group 60-79. Blood pressure increases with age, presence of the co-morbid condition, body weight, and lifestyle modification. The cause of hypertension may be known in some individuals whereas in most of the patients the cause is unknown. The individuals must be made aware of hypertension and directions about management with drugs and non-pharmacological implementation. The presence of hypertension for years may lead to further complications which if managed and monitored regularly can reduce risk. During the study period, 92 individuals were stage 1 (36.8) hypertensive followed by stage 2 (29.6%), elevated (15.2%), and normal (9.6%). The most commonly prescribed drugs in the study were Telmisartan (22.8%), Amlodipine (2.8%), Furosemide (2.4), Nifedipine (1.4), Captopril (1.4%), Metoprolol (0.8%), and Torsemide (0.8%) followed by losartan, Olmesartan, propranolol, ramipril, terlipressin, atenolol, valsartan, carvedilol, mannitol, vasopressin, and bisoprolol. Based on JNC 8 guideline the rationality of drugs obtained was 74.8%.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.